Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Status:
Completed
Trial end date:
2017-08-24
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral
midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia
(MCL) with or without an Associated Hematological clonal Non-Mast cell lineage Disease
(AHNMD).